SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

BACKGROUND: In ambulatory patients with cancer with asymptomatic or pauci-symptomatic SARS-CoV-2 infection, the safety of targeted therapies (TTs), chemotherapy (CT) or immune checkpoint inhibitors (ICIs) therapy is still unknown. MATERIAL AND METHODS: From the start of the first epidemic wave of SA...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Mandala, Mario, Lorigan, Paul, De Luca, Matilde, Bianchetti, Andrea, Merelli, Barbara, Bettini, Anna Cecilia, Bonomi, Lucia, Nahm, Sharon, Vitale, Maria Grazia, Negrini, Giorgia, Di Croce, Andrea, Ascierto, Paolo Antonio, Rulli, Eliana, Tondini, Carlo Alberto
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2021
Matèries:
Clinical/Translational Cancer Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7887862/
https://ncbi.nlm.nih.gov/pubmed/33593827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001694
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars